NHS England is undertaking a review of the current processes and commercial models which support the prescribing and supply of wound products listed in Part IX of the Drug Tariff. This review is guided by the National Wound Care Strategy Programme recommendations to address unwarranted variation, improve consistency, and ensure the best possible outcomes for patients and value for the NHS. As part of this review, we are seeking…

You must be logged in to view the rest of this content, click here to login

Don't have an account, click to sign up for our 14-day free trial.